Stories

Rare diseases are more common than most people imagine, in how many lives they touch and in how profoundly they shape everyday life for patients and families. Behind every diagnosis is a person navigating far more than symptoms: daily routines transformed, ambitions redefined, misunderstanding and isolation to navigate and families adapting to uncertainty with resilience and hope.

New in our A Life in Science series, we hear from Florence Meyer-Losic, Vice President and Head of Translational Sciences, about her journey from veterinary medicine to human research. She highlights the importance of adaptability, continuous learning, and diverse expertise in building successful teams that deliver innovative treatments for patients.

FY 2025 was a year of strong execution and robust performance across all therapeutic areas, driving significant topline growth and reinforcing the company’s strategic momentum. Total sales grew 10.9% at constant exchange rates (CER), supported by a solid 7.5% growth in Q4.

New in our A Life in Science series, we hear from Eli Leo, Early Development Asset Lead, about how teamwork, creativity, and even failure fuel progress in research. From seeing herself as a conductor guiding scientists like an orchestra to learning from the 98% of experiments that do not succeed, she shows how resilience and collaboration create meaningful breakthroughs for patients.

Before a medicine reaches patients, its promise must be measured against its risks. For Lineu Domit, safety physician in Ipsen’s Global Patient Safety team, this balance is the essence of early development.